One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...